Guidance regarding MHRA alert 20 February
Hyoscine butylbromide (Buscopan®) injection: risk of serious adverse effects in patients with underlying cardiac disease
Date: 2017
Date: 2017
Publication
Following receiving reports of the deaths of eight patients who received intravenous or intramuscular injections of Buscopan®, the Medicines and Healthcare Products Regulatory Agency (MHRA) issued an alert advising of a very small risk of serious adverse reactions in patients with underlying cardiac disease.
This is a joint position statement from The Royal College of Radiologists and the British Society of Gastrointestinal and Abdominal Radiologists in response to this alert.